secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGILE THERAPEUTICS INC (—)
CIK:        0001261249
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001558370-23-002116
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agile Therapeutics restates 2021-2022 financials; net loss overstated by $3.8M and $23.7M
--------------------------------------------------------------------------------

- Audit committee concluded warrants issued in 2021-2022 were improperly classified as equity; should be liabilities at fair value.
- Net loss overstated by $3.8M for FY2021 and $23.7M for nine months ended Sep 30, 2022; no impact on revenue, cash, or operating expenses.
- Company expects to report at least one material weakness in internal controls; financial statements for those periods should no longer be relied upon.
- Nasdaq granted 180-day extension until Aug 14, 2023 to regain minimum $1.00 bid price; shares continue trading on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1261249/000155837023002116/0001558370-23-002116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1261249/000155837023002116/agrx-20230223x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-002116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer